Drug intelligence / Profile preview

Crx-1

Development stage: Preclinical
Lead developer: Cryptyx Biosciences
Modality: Small Molecules

Overview

**Crx-1** is an investigational natural product-derived **small molecule** anti-infective being developed by **Cryptyx Biosciences** for **Clostridioides difficile infection** and **colitis**. It is listed in the company's pipeline at the **discovery** stage. Cryptyx describes the candidate as having a **dual mode of action**, but has not publicly disclosed a specific molecular target or detailed target-based mechanism. Company materials also state that Crx-1 is intended to provide activity superior to standard C. difficile therapies such as vancomycin, fidaxomicin, and metronidazole.

Beyond the preview

Go deeper on Crx-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crx-1.

Explore the full profile